LIK.XETRA Limes Schlosskliniken AG
- Market cap
- EUR 153M
- P/E
- 28.1x
- P/B
- 6.36x
- ROE
- 51.4%
- Dividend yield
- 1.89%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is LIK.XETRA undervalued?
Graham numberLIK.XETRA trades 182.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Limes Schlosskliniken AG fundamental analysis
No fundamental analysis for Limes Schlosskliniken AG yet.
Limes Schlosskliniken AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Limes Schlosskliniken AG
LIMES Schlosskliniken AG operates private clinics for psychiatry, psychotherapy, and psychosomatics services in Germany, Switzerland, Italy, and Liechtenstein. The company focuses on the treatment of stress-related illnesses; and mental and psychological disorders, such as depression, acute burnout, affective disorders, trauma/PTSD, anxiety disorders, attention deficit hyperactivity disorder, personality disorder, chronic pain, psychoses, obsessive compulsive disorder, sleep…
Full company profileLimes Schlosskliniken AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Limes Schlosskliniken AG annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 6.54M | 7.56M | 8.18M | 11.0M | 23.4M | 28.8M | 37.2M | 37.5M | 50.0M | 119M |
| Gross Profit | 1.59M | 2.27M | 2.08M | 2.80M | 8.37M | 10.8M | 16.2M | 34.5M | 19.1M | 48.2M |
| Operating Income | -716K | -927K | -541K | -428K | 4.53M | 6.00M | 5.03M | 4.29M | 9.31M | 20.2M |
| EBITDA | -486K | -129K | 263K | 838K | 6.02M | 8.65M | 7.67M | 7.05M | 12.8M | 28.0M |
| Net Income | -1.25M | -1.46M | -825K | -694K | 3.94M | 4.20M | 3.40M | 3.11M | 5.69M | 12.5M |
| EPS | -4.51 | -5.26 | -2.81 | -2.37 | 13 | 14 | 12 | 11 | 19 | 42 |
| Balance Sheet | ||||||||||
| Total Assets | 9.80M | 9.62M | 9.52M | 11.8M | 18.4M | 26.6M | 33.2M | 38.6M | 45.2M | 43.5M |
| Total Liabilities | 2.78M | 563K | 6.15M | 9.11M | 12.1M | 15.5M | 16.6M | 18.7M | 18.3M | 17.6M |
| Shareholders' Equity | -1.80M | -3.21M | 3.37M | 2.68M | 6.31M | 11.1M | 15.1M | 18.3M | 25.3M | 24.3M |
| Cash & Short-term Investments | 416K | 1.45M | 1.23M | 2.68M | 2.48M | 10.9M | 8.52M | 10.9M | 10.3M | 8.24M |
| Total Debt | 90.19 | - | 5.34M | 3.85M | 4.36M | 9.04M | 10.1M | 10.5M | 10.7M | 8.76M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 460K | 1.60M | 1.61M | 759K | 4.55M | 7.70M | 6.29M | 7.46M | 9.38M | 21.2M |
| Capital Expenditure | 0.00 | 1.76M | 1.76M | 1.76M | 6.38M | 1.35M | 9.81M | 4.98M | 8.63M | 2.67M |
| Free Cash Flow | 460K | 1.60M | 1.61M | -1.00M | -1.83M | 6.35M | -3.51M | 2.48M | 740K | 18.5M |
| Ratios | ||||||||||
| ROE | - | - | -24.5% | -25.9% | 62.5% | 37.9% | 22.5% | 17.0% | 22.5% | 51.4% |
| ROA | -12.8% | -15.2% | -8.7% | -5.9% | 21.4% | 15.8% | 10.2% | 8.1% | 12.6% | 28.8% |
| Net Profit Margin | -19.2% | -19.3% | -10.1% | -6.3% | 16.8% | 14.6% | 9.1% | 8.3% | 11.4% | 10.5% |
| Debt to Equity | - | - | 1.58x | 1.44x | 0.69x | 0.81x | 0.67x | 0.57x | 0.42x | 0.36x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Limes Schlosskliniken AG dividends
- Dividend yield
- 1.89%
- Forward dividend
- 10.00 EUR
- Payout ratio
- -
- Ex-dividend date
- Jun 22, 2026
Who owns Limes Schlosskliniken AG
- Insiders 70.27%
- Institutions 6.85%
- Public & others 22.88%
- Shares outstanding 298K
- Free float 293K
Limes Schlosskliniken AG company profile
- Company name
- Limes Schlosskliniken AG
- Ticker
- LIK.XETRA
- ISIN
- DE000A0JDBC7
- Exchange
- XETRA Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 314
- Fiscal year end
- December
- Address
- Kaiser-Wilhelm-Ring 26, Cologne, Germany, 50672
- Phone
- 49 221 669 615 0
- Website
- limes-schlosskliniken.de
About Limes Schlosskliniken AG
LIMES Schlosskliniken AG operates private clinics for psychiatry, psychotherapy, and psychosomatics services in Germany, Switzerland, Italy, and Liechtenstein. The company focuses on the treatment of stress-related illnesses; and mental and psychological disorders, such as depression, acute burnout, affective disorders, trauma/PTSD, anxiety disorders, attention deficit hyperactivity disorder, personality disorder, chronic pain, psychoses, obsessive compulsive disorder, sleep disorder, somatoform disorder, and sports psychiatry. The company was formerly known as GMF Capital AG and changed its name to LIMES Schlosskliniken AG in December 2005. LIMES Schlosskliniken AG was founded in 2005 and is headquartered in Cologne, Germany. The company operates as a subsidiary of GMF Capital GmbH.
Limes Schlosskliniken AG management
3- Dr. Gert Michael FrankCEO, Member of the Management Board & Director
- Dr. Kjell Brolund-Spaether M.D.Member of the Management Board
- Ralf Kruger M.D.Chief Physician